Signatures (of Response) to Environmental Exposures

Similar documents
Leveraging the field effect for precision molecular diagnostics: Opportunities and Challenges

Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer

The New England Journal of Medicine. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer

A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer

micrornas (mirna) and Biomarkers

genomics for systems biology / ISB2020 RNA sequencing (RNA-seq)

John F Brothers 1,2*, Kahkeshan Hijazi 1,2, Celine Mascaux 3, Randa A El-Zein 4, Margaret R Spitz 4 and Avrum Spira 1,2

Are Genomics and proteomics biomarkers ready for prime time? National Cancer Policy Forum workshop Pierre P. Massion, MD

Epigenetics. Jenny van Dongen Vrije Universiteit (VU) Amsterdam Boulder, Friday march 10, 2017

IPA Advanced Training Course

RNA-seq Introduction

TITLE: Single-Cell RNA Sequencing of the Bronchial Epithelium in Smokers with Lung Cancer

Identification of heritable genetic risk factors for bladder cancer through genome-wide association studies (GWAS)

Screening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery

CONTRACTING ORGANIZATION: University of California, Los Angeles, Los Angeles, CA 90095

Screening for Lung Cancer - State of the Art

Christine Argento, MD Interventional Pulmonology Emory University

COPD: Genomic Biomarker Status and Challenge Scoring

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Molecular Profiles for Lung Cancer Pathogenesis and Detection in US Veterans

TITLE: Detection of Early lung Cancer Among Military Personnel (DECAMP) CONTRACTING ORGANIZATION: Boston University Boston, MA 02118

Medical Policy. MP Molecular Testing in the Management of Pulmonary Nodules

RNA- seq Introduc1on. Promises and pi7alls

CONTRACTING ORGANIZATION: University of California, Los Angeles Los Angeles, CA 90095

RASA: Robust Alternative Splicing Analysis for Human Transcriptome Arrays

Molecular Cytology That Transforms Patient Care. William Blair 35 th Annual Growth Stock Conference June 9, 2015

Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers

Simple, rapid, and reliable RNA sequencing

Epigenetic Markers for Transplacental Exposure to Airborne Polycyclic Aromatic Hydrocarbons (PAHs( PAHs) ) and Childhood Asthma.

Ambient temperature regulated flowering time

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

Metabolomics for Characterizing the Human Exposome: The need for a unified and high-throughput way to ascertain environmental exposures

Healthy Lungs. Presented by: Brandi Bishop, RN and Patty Decker, RRT, RCP

Molecular Testing in the Management of Pulmonary Nodules

Computer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015

Molecular Testing in the Management of Pulmonary Nodules

Biomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club

An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup

Profiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola

Assaying micrornas in biofluids for detection of drug induced cardiac injury. HESI Annual Meeting State of the Science Session June 8, 2011

Small RNA-Seq and profiling

RECENT ADVANCES IN THE TREATMENT OF OBSTRUCTIVE JAUNDICE RECENT ADVANCES IN THE MANAGEMENT OF CHRONIC OBSTRUCTIVE

SMOKING AND CANCER RISK

Set the stage: Genomics technology. Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands

Diagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD. November 18, 2017

Approximately 1.25 billion people smoke cigarettes daily

How to address tumour heterogeneity in next generation oncology trials

MicroRNA and Male Infertility: A Potential for Diagnosis

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, MD

Small RNAs and how to analyze them using sequencing

SMOKING AND CANCER RISK

The rat microrna body atlas: mirna identification and characterization

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy

DeconRNASeq: A Statistical Framework for Deconvolution of Heterogeneous Tissue Samples Based on mrna-seq data

Breast cancer. Risk factors you cannot change include: Treatment Plan Selection. Inferring Transcriptional Module from Breast Cancer Profile Data

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

P. Tang ( 鄧致剛 ); PJ Huang ( 黄栢榕 ) g( ); g ( ) Bioinformatics Center, Chang Gung University.

Nicotine dependence treatment: A translational research approach

Lung cancer is the leading cause of cancer death in the. Clinical Impact of High-Throughput Gene Expression Studies in Lung Cancer

AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification

COPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI

RECENT ADVANCES IN THE MOLECULAR DIAGNOSIS OF BREAST CANCER

TITLE: Total RNA Sequencing Analysis of DCIS Progressing to Invasive Breast Cancer.

Health Effects of Passive Smoking

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

Unconscious exchange of air between lungs and the external environment Breathing

On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles

B Unit III Notes 6, 7 and 8

Introduction. Introduction

Case 1:99-cv GK Document Filed 01/10/14 Page 1 of 11. Exhibit D. Online newspaper exemplars

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC

Synthetic microrna Reference Standards Genomics Research Group ABRF 2015

April 5, :45 AM 1:45 PM MARRIOTT MARQUIS HOTEL & MARINA, MIRAMAR VIGNETTE 1 VIGNETTE 2 VIGNETTE 3* VIGNETTE 4* VIGNETTE 5*

CONTRACTING ORGANIZATION: Joan & Sanford I. Weill Medical College of Cornell University New York, NY 10065

Disclosures. Overview. Selection the most accurate statement: Updates in Lung Cancer Screening 5/26/17. No Financial Disclosures

Combining gene and mirna expression for early detection of lung cancer from whole blood samples in PAXgene

Present value cost-savings to Medicaid over 25 years

The value of Omics to chemical risk assessment

Case-Control Studies

a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation,

Investigating rare diseases with Agilent NGS solutions

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

Causal modeling in the lung Combining multiple data types to enhance clinical diagnosis

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

Gene transcript profiles to diagnose infectious diseases. ESCMID Conference on Diagnosing Infectious Diseases: Future and Innovation

Bronchitis. Anatomy of the Lungs The lungs allow us to fill our blood with oxygen. The oxygen we breathe is absorbed into our blood in the lungs.

microrna Presented for: Presented by: Date:

Using Ozone to Validate a. Toxicity Testing

Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management

Bi 8 Lecture 17. interference. Ellen Rothenberg 1 March 2016

An Examination of Factors Affecting Incidence and Survival in Respiratory Cancers. Katie Frank Roberto Perez Mentor: Dr. Kate Cowles.

Identifying microrna signatures of chemo-resistance in colorectal cancer

ncounter Assay Automated Process Immobilize and align reporter for image collecting and barcode counting ncounter Prep Station

Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer

Complements asthma therapy NOT a CURE for Severe. Non pharmacologic treatment of asthma. limits the ability of the airways to constrict.

What is Severe Persistent Asthma? What is Bronchial Thermoplasty Non pharmacologic treatment of asthma

September 23, The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development

Provocative Questions from a Clinical Perspective

Transcription:

Gene-expression Profiles as Signatures (of Response) to Environmental Exposures Smoking and the airway field of injury as a novel paradigm for the exposome Avrum Spira, M.D., M.Sc. Section of Computational Biomedicine The Pulmonary Center Boston University Medical Center

Disclosure Founder and consultant to Allegro Diagnostics Inc.

The Airway Field of Injury Hypothesis Smoking (and other inhaled exposures) alters epithelial cell gene expression throughout the respiratory tract abnormal cells Variability in epithelial cell genomic response to and damage from smoking linked to tobacco-associated lung disease

The bronchial airway transcriptome in Smoking impacts airway gene expression -PNAS 2004; NAR 2005; smoking and lung cancer Subset of changes are irreversible upon cessation and can serve as biomarker of past exposure - Genome Biology 2007 Airway gene expression can serve as an early diagnostic biomarker for lung cancer - Nature Medicine 2007; Cancer Prevention Research 2008 RNA- U133A Affymetrix array (~22,500 genes)

The reversible and irreversible impact of smoking on bronchial airway gene-expression Biomarker of past exposure

Airway gene-expression as a diagnostic biomarker for lung cancer no cancer cancer 1. 5. 2. 80 gene biomarker that can distinguish smokers with and without lung cancer -sensitivity 80%; specificity 84% in two independent cohorts (n=87) -90% sensitive for stage 1 disease -95% sensitivity and 95% NPV when combined with cytology obtained at bronchoscopy -independent of clinical and radiographic predictors of disease Validation study of 80 gene biomarker on large independent multicenter Cancer?? cohort by Allegro Diagnostics Inc. 800 subjects recruited at 14 centers in US, Canada and Europe IDE filed with FDA Brush cytologically-normal airway Extract & process Bronchoscopy performed as initial diagnostic test Cytology obtained has low sensitivity especially for early stage disease. This results in clinical dilemma as to who should go for surgical resection. 3. epithelial ihli lcells in mainstem bronchus 4. RNA using microarray Nature Medicine 2007; CAPR 2008

Extending the field to the upper airway

Mouth Scraper Biotechniques 2004

Technique for Obtaining RNA from Nasal Mucosal Brushings 1% Lidocaine topically to inferior turbinate Cytosoft brushings from interior of inferior turbinate Immerse in RNA later

The nose-mouth-airway study as part of NIEHS Genes and Environment Health Initiative Collect bronchial, buccal, and nasal epithelial cells from current (n=13) and never (n=14) smokers Large (>200nts) and small RNAs isolated from same samples Large RNA run on all-exon arrays (1.4 million exons) Small RNAs run on mirna microarrays (476 micrornas) Zhang et al. Physiological Genomics 2010

Genes that change in common across respiratory tract in smokers Gene expression= smoking status + tissue type + smoking*tissue + patient(random effect) Bronch Nose Mouth current never current never current never

The nose-bronch relationship nose bronch

Upper airway biomarkers developed as part of the GEI Nasal and buccal gene-expression as biomarker of past exposure Nasal biomarker of second-hand smoke exposure Buccal biomarker of cumulative exposure ( packyrs) to tobacco smoke Nasal gene-expression signature post-smoking cessation

Why develop a biomarker of secondhand smoke exposure 20-30% increased risk of heart disease and lung cancer Significant morbidity in children exposed -lung and ear infections -asthma attacks (number and severity) CD

Moving nasal biomarkers of secondhand exposure to children Columbia Center for Children s Environmental Health (CCCEH) cohort Disease Investigation Through Specialized Clinically-Oriented Ventures in Environmental Research (DISCOVER) cohort

Developing a gene-expression signature of smoking cessation Kinetics of airway gene-expression changes post-cessation ti within an individual id Baseline signature to compare with PREP Quit day Current Smokers Time =0 4weeks 8weeks 16weeks 24 weeks

Leverage existing clinical trial sponsored by AllegroDx Inc as part of EDRN. AllegroDx Inc is validating diagnostic gene-expression signature for lung cancer -IDE filed with FDA 600 current and former smokers undergoing bronchoscopy for suspect lung cancer at 14 medical center in US, Canada, and Europe mirna/mrna from nose isolated at CLIA facility and shipped to BU mrna arrays and mirna-seq mrna signature validatio

Extending the airway field of injury to microrna Small, non-coding RNAs ~22-25 25 nts microrna Bind to 3 -UTR of mrna Downregulates gene through several mechanisms Implicated in development, cell stress response, cancer. A MORE ROBUST BIOMARKER?? -relatively resistant to degradation -microrna changes upstream to many mrna mrna X Target Degradation Translational repression protein Esquela-Kerscher et al.(2006) Nature Reviews Cancer 6, 259 269

Impact of smoking on bronchial airway microrna expression -NCODE array -~500 human mirna in triplicate MicroRNA regulate the gene-expression response to smoking Schembri et al PNAS. 2009

Microarray vs. RNA-seq Microarrays Limited by prior knowledge on what is expressed Analog output with limited dynamic range Cross hybridization RNA-seq Pure discovery** Digital output with large dynamic range Alt splicing SNP in exons Cost $$ Throughput h moderate Computation ++ Cost $$$$$ Throughput low Computation ++++

Deep sequencing the airway transcriptome Large RNA sequenced on Illumina Solexa system -36 base pair reads -30 million reads per sample Small RNA (15-40 bp) sequenced on ABI SOLID platform -30 base pair sequence 4 pools: Never smoker, current smoker, smoker with lung cancer, smoker with benign lung disease -200 million reads per run (4 samples multiplexed in single run)

mrna-seq identifies novel smoking- and cancerrelated gene expression changes in the airway Beane et al. 2011

Summary Airway epithelial gene expression reflects host response to and damage from tobacco smoke Heterogeneity in genomic response may serve as early diagnostic biomarker for lung cancer (and COPD) This field of injury extends to the nose and mouth epithelium, although the nose appears to be a better surrogate to the bronchus Upper airway gene expression can serve as biomarker of tobacco smoke exposure and potentially a non-invasive lung cancer marker Ever exposure Second dhand exposure Post-smoking cessation RNA-seq may serve as the most comprehensive discovery tool for transcriptomic biomarkers of exposure

Acknowledgements Boston University Marc Lenburg Univ of Utah: Andrea Bild Jerome Brody NCI: Eva Szabo, Nat Rothman, Qing Lan Joshua Campbell Vanderbilt University: Pierre Massion Gang Liu Sherry Zhang Hopkins: Pat Breysse, Greg Diette Ji Zhang Columbia University: Steve Chillrud, Rachel Miller Joe Guerrein UCLA: Steve Dubinett, Bi Brigitte i Adam Gower Gomperts LRRI: Steve Belinsky Christina Anderlind Catalina Perdomo NIEHS: Dan Shaughnessy, David Balshaw Funded by NIEHS, NCI/EDRN, NHLBI, DOD